Introduction
Cardiovascular disease is the leading cause of death worldwide.
1 It is largely preventable, and biomarkers have received growing attention in attempts to improve the prediction of risk for atherothrombotic events. 2 Particularly, biomarkers reflecting cardiac volume or pressure overload appear promising in terms of risk stratification and prediction of subsequent CHD events and heart failure. 3, 4 Besides the natriuretic peptides 5 , midregional proadrenomedullin (MR-proADM) has now moved into the centre of interest in this area. MR-proADM is a stable and surrogate marker for adrenomedullin (ADM) release. 6 ADM is a peptide hormone that acts as a vasodilator and plays important roles in the microcirculation and in endothelial dysfunction. 7, 8 Plasma ADM concentrations are increased with myocardial infarction and correlate with the severity of associated heart failure. 9, 10 In patients with chronic heart failure, MR-proADM has been shown to be an independent predictor of mortality and to provide additional prognostic information beyond established biomarkers. [11] [12] [13] Increased MR-proADM concentrations have also been associated with a worse outcome in patients with acute dyspnoea and suspected heart failure. 14 However although MR-proADM is a powerful predictor of adverse outcomes in patients after myocardial infarction 15 and in CHD patients, 16 its importance in long-term follow-up of stable CHD patients, especially any association with incident heart failure, still needs further examination. Therefore, the aim of the present study was to assess the ability of MR-proADM to predict the risk of future major CHD events and heart failure in patients who were stable after previous myocardial infarction or unstable angina and also whether concentration changes over time translated into differences in risk of subsequent events. In both contexts, models adjusted for known prognostic variables including brain natriuretic peptide (BNP).
Methods

Study design and patients
The design and results of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study has been described elsewhere. 17 Briefly, 9,014 patients with an acute myocardial infarction or hospitalisation for unstable angina 3-36 months previously were enrolled. Participants were aged between 31 and 75 years and were recruited from 87 centres in Australia and New Zealand. Baseline total cholesterol concentration was required to be 4-7 mmol/L (155-271 mg/dL) and fasting triglyceride concentration <5 mmol/L (445 mg/dL). Patients with a clinically significant medical or surgical event within the three months before study entry, current cardiac failure, renal or hepatic disease, or taking lipid-lowering agents were excluded from the study. Ejection fraction was not measured routinely prior to randomisation, but if this was documented to be <25%, such patients were also excluded.
Coronary anatomy and whether or not patients had functional evidence of myocardial ischaemia was also unknown.
After an 8-week, single-blinded placebo run-in phase patients were randomised to either 40 mg pravastatin daily or matching placebo between June 1990 and December 1992. Both groups received dietary advice. Patients were followed-up for a median of 6.0 years. Vital status was ascertained in all but one patient.
Baseline data and a multivariate model were used to calculate a "global risk score" for each patient to rank the risk of CHD mortality or non-fatal myocardial infarction. 18 Total and highdensity lipoprotein (HDL)-cholesterol concentrations, age, gender, smoking status, whether myocardial infarction or unstable angina was the qualifying event, previous coronary revascularisation procedures, diabetes mellitus, hypertension, and previous stroke were the independent significant predictors used to calculate the global risk score.
Laboratory methods
Biomarker measurements were available at baseline in 7,863 patients (6,530 male, 1,333 female). A total of 6,658 patients also had a MR-proADM assay available at one year after their randomisation to either pravastatin or placebo.
EDTA blood was drawn after a 12 hour fasting period. Samples were stored at -70 °C until final analyses. High density lipoprotein -cholesterol and triglyceride levels were measured directly. Low-density lipoprotein (LDL)-cholesterol was estimated indirectly, using the Friedewald formula. skewed, and also some values were below the lower limit at baseline and year 1. For these reasons and as pre-specified in the biomarker protocol, analyses were performed using quartiles.
BNP was measured using the sandwich-immunoassay/ADVIA Centaur BNP test kit (Siemens Healthcare) on an ADVIA Centaur XP with an assay range of 0-5000pg/ml. The interassay coefficient of variation was between 2.6 and 5.1%.
Biochemical analyses were performed blinded to randomised treatment.
Study outcomes
The primary pre-specified outcome for LIPID biomarker analyses was a composite of CHD death and non-fatal myocardial infarction (major CHD events). Additionally, endpoints for the present study included incident heart failure (hospitalisation or death from heart failure, as diagnosed by ICD-9 codes (4280, 4281, 4289)), and all-cause mortality. Myocardial infarction was diagnosed by development of new pathological Q-waves of ≥0.03 seconds in at least 2 contiguous electrocardiographic leads or presence of at least two of the following: a history of typical ischaemic pain lasting for ≥15 minutes and unresponsive to sublingual nitrates; elevation of creatinine kinase MB-isoform >2 times the upper limit of normal; evolution of ST-T changes. All deaths, myocardial infarctions, and strokes were reviewed by Outcomes Assessment Committees whose members were blinded to treatment assignment. All analyses were pre-specified in a biomarker protocol. The trial and the biomarker analyses were conceived, managed, and analysed independently of the sponsor.
Informed consent was obtained from each patient prior to randomisation in the LIPID study, and also prior to samples being taken for biomarker analyses. 
Statistical Methods
Continuous variables are described as means (with standard deviations) or medians (with 25th and 75th percentiles). As pre-specified in the biomarker analysis plan, MR-proADM was concentrations were compared between treatment groups using a Wilcoxon signed rank test.
The relationship between baseline MR-proADM and other baseline risk factors was assessed using Spearman's rank correlation coefficient.
The association between baseline MR-proADM quartiles and outcome was assessed using The relationship between change in biomarker concentration and CHD events after 12 months was assessed using Cox regression in a landmark model that included baseline risk factors and baseline MR-proADM concentration. Whether MR-proADM improved discrimination between those who did and those who did not develop events was assessed using the C statistic which was calculated from the time-to-event analysis 19 , and also Net Reclassification Improvement (NRI). To assess risk reclassification following the addition of MR-proADM, the categories used were <7.5%, 7.5% to <10%, 10% to <15% and ≥15% risk of all endpoints during follow-up at 5 years. Improvement in classification was defined as upward movement in risk category in patients who experienced an event, or movement to a lower risk category in those who did not experience such an event.
Finally models testing the prognostic value of both baseline MR-proADM and its change over 12 months were further adjusted for concentrations of BNP and its change.
The pre-specified level of significance was 0.05, except in the context of interaction p-values where this was instead 0.01 due to the large number of comparisons.
For the primary endpoint of major CHD events, of which there were 1100, there was 80% power to detect a hazard ratio of at least 1.19.
Analyses were carried out using SAS 9.2 SAS Institute Inc., Cary, NC, USA.
Results
Baseline characteristics stratified by baseline MR-proADM concentrations Table 1 shows the baseline demographics, cardiovascular risk factors, and clinical features associated with atherosclerotic cardiovascular disease categorised by MR-proADM quartiles.
Individuals with higher MR-proADM concentrations were significantly older and more frequently female (both p<0.001). Further, patients from the higher MR-proADM quartiles more often had recognised cardiovascular risk factors (hypertension, obesity, previous stroke, lower HDL-cholesterol concentrations) and impaired renal function (lower estimated glomerular filtration rate), had a higher estimated global risk score and were less likely to have undergone coronary revascularisation (all p<0.001). Those with the highest MRproADM concentrations were also more likely to be treated at baseline with antihypertensive medication (angiotensin converting enzyme (ACE) inhibitors, beta-blockers, calcium antagonists) (all p<0.001) and less likely to be treated with aspirin (p<0.01).
MR-proADM showed a moderate correlation with BNP (r=0.54), and a modest correlation with age at randomisation (r=0.36), serum creatinine (r=0.30), and estimated glomerular filtration rate (eGFR) (r=-0.40) (all p<0.001) ( Table 2) .
Association between baseline MR-proADM concentration and outcomes
Increasing baseline MR-proADM quartiles were strongly associated with the subsequent risk of the composite endpoint of major CHD events (CHD death and non-fatal myocardial infarction) (highest quartile compared to first quartile (HR 1.52, 95% CI 1.26-1.84; p<0.001) and also CHD death (HR 2.21, 95% CI 1.67-2.92; p<0.001), heart failure (HR 2.30, 95% CI 1.78-2.97; p<0.001), and all-cause mortality (HR 1.82, 95% CI 1.49-2.23; p<0.001). There was no association with non-fatal myocardial infarction alone (HR 1.11, 95% CI 0.86-1.42, p=0.43) ( Table 3) . Table 3 shows that after additional adjustment for BNP concentration, the associations of baseline MR-proADM concentration appeared slightly attenuated but still remained significant for major CHD events, CHD death, heart failure and all-cause mortality.
Associations with change in MR-proADM concentrations from baseline to one year An increase in MR-proADM concentration in the first year >0.0565 nmol/l (the highest quartile of change) was associated with a higher risk of major CHD events compared to those individuals with the greatest reduction in concentration of MR-proADM ≤-0.0665 nmol/l (lowest quartile) (HR 1.34, 95%CI 1.08-1.66; p=0.007). This was primarily due to the increased risk of non-fatal myocardial infarction (HR 1.50, 95 % CI 1.12-2.03; p=0.007).
Strong associations of change in MR-proADM were also observed for incident heart failure (HR 1.78, 95% CI 1.37-2.30, p<0.001) and all-cause mortality (HR 1.42, 1.15-1.76, p=0.001) ( Table 4 ).
As shown in Table 4 , after additional adjustment for baseline and change in BNP concentration, the association of outcome with change of MR-proADM concentration after one year remained significant for incident heart failure and all-cause mortality.
Metrics of discrimination and reclassification for baseline MR-proADM and outcomes
Adding baseline MR-proADM concentration to the set of baseline variables improved discrimination and reclassification for CHD death (C statistic 0. Table 5) .
Interaction with treatment effect of pravastatin Table 6 compares the associations of baseline MR-proADM quartiles with study outcomes in both treatment groups. The relative treatment effect of pravastatin was comparable across each baseline quartile of MR-proADM concentrations for each outcome measure, with no evidence of any significant interaction. This constant relative effect translated into an increasing absolute benefit of pravastatin with increasing quartile of MR-proADM, i.e. number (Table 7) . After one year of treatment, MR-proADM concentration decreased by a small but significantly greater extent in those patients taking pravastatin (p=0.03).There were no differences between genders in the magnitude of this change in MRproADM with pravastatin.
Discussion
The present data from the large, randomised, placebo-controlled LIPID study focussed on the predictive value of baseline MR-proADM concentration and the change in its concentration after one year in patients with stable CHD. In this prespecified biomarker analysis we showed an association between baseline MR-proADM concentrations and the incidence of subsequent major clinical events. Higher baseline MR-proADM concentrations were an independent predictor of future major CHD events, particularly CHD death, and also predicted heart failure and all-cause mortality. In addition, patients who had greater reduction in MR-proADM concentrations after one year, had a lower risk of CHD events, primarily due to a lower risk for non-fatal myocardial infarction, and also a lower risk of subsequent heart failure and all-cause mortality. Despite the correlation of MR-proADM with BNP concentration, the associations of baseline MR-proADM concentration persisted after additional significant adjustment for baseline BNP. Interestingly, the change in MR-proADM after one year was still highly significant for subsequent heart failure hospitalisation or death after further adjusting for BNP concentration.
The findings related to the effect of change in MR-proADM on subsequent events are particularly noteworthy. This is a very important and robust test of the relevance of a biomarker, but is rarely assessed.
MR-proADM baseline concentrations added borderline significant discriminative effect beyond classical risk factors for CHD death and heart failure, but not for major CHD events or myocardial infarction. The absolute changes in C statistic were relatively small. The greatest risk reclassification was found for heart failure by adding the change of MR-proADM concentration after one year (NRI 5.60%). There were no significant differences in the relative treatment effect of pravastatin according to baseline MR-proADM quartiles.
Association of baseline MR-proADM with laboratory parameters and classical risk factors
Our finding that increased MR-proADM concentrations were associated with impaired renal function is consistent with previous studies. 20 MR-proADM was also associated with predictors of CHD mortality, including age, clinical evidence of severe cardiac and cerebrovascular disease (previous stroke, higher global risk score), hypertension, obesity, diabetes and BNP concentration. 13, 16, 18, 21 The correlation with BNP concentration is consistent with the findings of others.
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Associations of baseline MR-proADM concentrations and change of MR-proADM with cardiovascular outcomes
Results in earlier trials concerning the predictive value of adrenomedullin were ambiguous.
However, after the establishment of modern assays to detect stable precursors, MR-proADM has evolved into an important biomarker in cardiac risk prediction. . Patients with higher concentrations of MR-proADM were at increased risk of death and incident heart failure. In the LAMP studies, blood samples were drawn as early as 3 to 5 days after the qualifying event. In contrast in our present study, baseline blood samples were drawn at a median of 13.9 months (IQR 7.9, 25.0) after the qualifying event. Therefore MR-proADM concentrations in the LAMP studies may reflect the early pathophysiological and remodelling processes after myocardial infarction rather than testing their value as a prognostic marker in long-term follow-up in patients with stable CHD.
The present data showing that baseline MR-proADM concentrations predicted CHD death and heart failure, but not non-fatal myocardial infarction are in accordance with the findings of the AtheroGene Study which investigated MR-proADM concentrations in a smaller number of individuals (n=2,240) with stable angina or acute coronary syndrome and evaluated their prognostic impact on cardiovascular events during a follow-up period of almost 4 years. 16 In AtheroGene, MR-proADM concentrations were independently associated with fatal or nonfatal cardiovascular events.
Sabatine et al. 22 showed that in patients with stable CHD and preserved ejection fraction, biomarkers reflecting cardiovascular stress (e.g. MR-proADM, natriuretic peptides) were more predictive of CHD death and incident heart failure, than the composite of CHD death and myocardial infarction. This is similar to our findings.
In our study the association of MR-proADM concentrations with subsequent heart failure events was even stronger than for the primary endpoint of major CHD events. Since reduction in left ventricular function is a common result of the structural changes in the heart caused by CHD, our observations may be explained by the different pathophysiological processes involved. In animal models, MR-proADM is increased in response to pressure-and volume-overload and protects against fibrosis and hypertrophy. [26] [27] [28] This suggests a potential counter-regulatory effect protecting against structural cardiac changes. This is supported by our finding that patients who had the greatest reduction in MR-proADM concentration after one year compared to those with little change or increasing MR-proADM concentrations showed a reduced risk of major CHD events, non-fatal myocardial infarction, heart failure and all-cause mortality.
Of particular note, in the PEACE study 22 trandolapril was most effective in those individuals in the upper quartile of MR-proADM concentrations. This biomarker/therapy interaction was not observed for N-terminal pro-B-type natriuretic peptide. Our findings are also congruent with those in the HOPE biomarker study.
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What are the implications of these data?
Together with our observation that changes in MR-proADM concentrations can impact on incident heart failure and other major events even after adjusting for BNP concentration, MR-proADM may have the potential to inform therapeutic decision-making in stable CHD patients. Single baseline determination of MR-proADM, because it predicts death and heart failure as well as recurrent major CHD events, and serial assessment of the change of MRproADM potentially has important clinical utility. Furthermore, MR-proADM concentrations predict heart failure beyond clinical variables such as hypertension and body mass index, and additionally BNP concentration, and might guide the modification or intensity of therapy aimed at preventing or managing heart failure. However, this possibility of MR-proADM
guided therapy needs to be tested prospectively
Effect of pravastatin therapy
After one year of treatment with pravastatin, MR-proADM concentration decreased to a small but significantly greater extent in those patients taking pravastatin. It is possible but remains speculative whether this could partly contribute to the reduced risk for subsequent events in patients receiving statins.
The relative treatment effect of pravastatin on outcomes was very similar across each baseline quartile of MR-proADM. However, with increasing MR-proADM quartiles, the NNT decreased for all endpoints. Thus, patients in the higher MR-proADM quartiles experienced a greater absolute benefit because of their higher risk. This finding suggests that such patients need the most intensive surveillance with regard to modification of cardiovascular risk factors and compliance with secondary preventive strategies. Recognising and treating aggressively on the basis of these findings may result in major benefits for individuals with highly elevated MR-proADM concentrations.
Study limitations
The LIPID study was conducted some years ago. However the cohort has ongoing major relevance to current clinical management since it provides a unique dataset with long-term follow-up of a large group of typical CHD patients who had previously been admitted to hospital with myocardial infarction or unstable angina. Furthermore patients had a broad range of cholesterol levels reflecting those in usual clinical practice. Importantly there were relatively few exclusion criteria and of just over 11,000 screened patients, 9,014 were subsequently randomised to receive pravastatin or placebo. Biomarker levels were available in a high proportion, 7,863 patients at baseline and 6,658 after one year. Background therapy was also quite similar to therapies which are currently recommended, although usage of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers was less than in contemporary practice. Also use of beta-blockers and ACE inhibitors was by chance, higher in those with the highest MR-proADM levels. Since commencement of the LIPID trial the most significant changes in management of coronary heart disease patients have been dual antiplatelet therapy and the more frequent use of primary angioplasty in acute myocardial infarction. However these advances are less relevant to stable CHD patients, as were recruited to the LIPID study. However it is acknowledged that preservation of left ventricular function could modulate the impact of the biomarkers investigated. In addition, use of implantable cardioverter defibrillators have improved survival of selected CHD patients, although those known to have a very low ejection fraction were excluded from the LIPID study. Although diagnostic criteria for myocardial infarction have evolved, the LIPID cohort still represents stable CHD patients randomised at a median of 1 year after their qualifying event.
The models used to assess the effects of change in MR-proADM were restricted to events after the 12 month sample was taken. Therefore, these data provide no information on very high risk patients, who had an event which may have been fatal, within the first 12 months after randomisation. Also the LIPID study included predominantly males (83%). This is of particular interest since females had higher MR-proADM concentrations. Gender-specific analyses would be of interest in future studies.
Finally, the diagnosis of heart failure at baseline was based on clinical assessment rather than echocardiographic or angiographic parameters. However, incident heart failure during follow-up was diagnosed on the basis of hard end-points, either need for hospitalisation or death due to heart failure.
Despite these limitations, we believe that the observed associations of both baseline MRproADM and its change after one year with major clinical outcomes, which importantly persisted after adjustment for BNP concentration, have major relevance for contemporary patient management and research.
Conclusions
In conclusion, determining MR-proADM baseline concentration in stable CHD patients with previous acute coronary syndromes may be a valuable tool for physicians to identify those at particular need for intensified surveillance of risk factors and for potential complications of CHD. This could also inform more intensive measures to improve compliance with statins and other evidence-based therapies. Evaluating the change of MR-proADM concentration during monitoring of patients may also help to identify patients at particular risk of incident heart failure beyond use of brain natriuretic peptides for this purpose. 
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